Trial Profile
Pharmacodynamic study of Erlotinib (Tarceva) in patients with mestastatic or locally advanced Epidermoid carcinoma of the head and neck.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 May 2011
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Head and neck cancer
- Focus Pharmacogenomic; Therapeutic Use
- 17 May 2011 New trial record